Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tapentadol controlled-release - Grunenthal

Drug Profile

Tapentadol controlled-release - Grunenthal

Alternative Names: BN200 ER; BN200 PR; CG 5503 ER; CG 5503 PR; JNS024ER; Nucynta ER; Palexia Depot; Palexia Retard; Palexia RP; Palexia SR; Palexia XR; R331333 PR; Tapenta; Tapentadol CR tamper-resistant formulation; Tapentadol CR TRF; Tapentadol ER PR2; Tapentadol ER prolonged-release 2; Tapentadol ER tamper-resistant formulation; Tapentadol ER TRF; Tapentadol extended release; Tapentadol PR; Tapentadol prolonged release; Tapentadol prolonged release granules; Yantil Retard

Latest Information Update: 15 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grunenthal
  • Developer Grunenthal; Janssen Pharmaceutical KK; Janssen Research & Development
  • Class Opioid analgesics; Phenols; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Alpha 2 adrenergic receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain; Diabetic neuropathies; Pain
  • Discontinued Neuropathic pain

Most Recent Events

  • 14 May 2019 9266652: info already covered, no updates
  • 28 Mar 2019 The United States Court of Appeals for the Federal Circuit rules in favour of Assetio Therapeutics against ANDAs for the NUCYNTA® franchise
  • 08 Nov 2018 Collegium entered into an amendment to the marketing agreement with Assertio Therapeutics for Tapentadol franchise
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top